Skip to main content

View full-text article in PMC

. 2011 Mar;3(1):19–29. doi: 10.3978/j.issn.2072-1439.2010.11.11

Table 2. Phase II/III clinical trials of TKIs in stage IIIB/IV NSCLC.

First author	N	Study arms	RR (%)	PFS weeks	P	OS months	P
Heymach [47]	1391	Docetaxel/placebo	27	12	<0.001	10.0	0.196
Heymach [47]	1391	Docetaxel/vandetanib	47^*	18.7	<0.001	10.6	0.196
de Boer [71]	534	Pemetrexed/placebo	8	11.9	0.108	9.2	0.219
de Boer [71]	534	Pemetrexed/vandetanib	19^*	17.6	0.108	10.5	0.219
Natale [72]	1240	Erlotinib	12	8.9	0.721	7.8	0.83
Natale [72]	1240	Vandetanib	12	11.3	0.721	6.9	0.83
Natale [46]		Gefitinib	1	8.1	0.013^**	6.1	0.83^**
Natale [46]		Vandetanib	8	11.9	0.025^***	7.4	0.34^***

*P<0.001; ** - one-sided; *** - two-sided